

# ForPatients

by Roche

Alzheimer's Disease (AD)

## A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease

**Trial Status**  
Terminated

**Trial Runs In**  
13 Countries

**Trial Identifier**  
NCT03289143 2017-001800-31  
GN39763

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This was a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's disease. An optional 96-week open-label extension period was available to participants who completed the double-blind treatment period and who, in the judgment of the investigator, would potentially benefit from open-label Semorinemab treatment.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

---

**NCT03289143 2017-001800-31 GN39763**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 50 Years & <= 80 Years

**Healthy Volunteers**  
No

---